BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance: Lipid-lowering treatment and glucose. International Journal of Clinical Practice 2011;65:1141-8. [DOI: 10.1111/j.1742-1241.2011.02779.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee JH, Kang HJ, Kim HS, Sohn DW, Oh BH, Park YB. Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial. Am J Cardiovasc Drugs 2013;13:343-51. [PMID: 23728830 DOI: 10.1007/s40256-013-0031-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. Eur J Clin Invest 2013;43:698-707. [PMID: 23600368 DOI: 10.1111/eci.12095] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
3 Muscogiuri G, Sarno G, Gastaldelli A, Savastano S, Ascione A, Colao A, Orio F. The good and bad effects of statins on insulin sensitivity and secretion. Endocr Res 2014;39:137-43. [PMID: 25208056 DOI: 10.3109/07435800.2014.952018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
4 Kostapanos MS, Mikhailidis DP, Elisaf MS. Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit. Future Cardiol. 2012;8:813-817. [PMID: 23176685 DOI: 10.2217/fca.12.64] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Bernardi A, Rocha VZ, Faria-Neto JR. Use of statins and the incidence of type 2 diabetes mellitus. Rev Assoc Med Bras (1992) 2015;61:375-80. [PMID: 26466221 DOI: 10.1590/1806-9282.61.04.375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opinion on Drug Safety 2015;14:1835-44. [DOI: 10.1517/14740338.2015.1096343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
7 Lee J, Hwang YC, Lee WJ, Won JC, Song KH, Park CY, Ahn KJ, Park JY. Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study. Diabetes Ther 2020;11:859-71. [PMID: 32065359 DOI: 10.1007/s13300-020-00778-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013;36:1236-40. [PMID: 23248196 DOI: 10.2337/dc12-1756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
9 Thongtang N, Tangkittikasem N, Samaithongcharoen K, Piyapromdee J, Srinonprasert V, Sriussadaporn S. Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes. Vasc Health Risk Manag 2020;16:367-77. [PMID: 33061398 DOI: 10.2147/VHRM.S270751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Stein EA, Raal F. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther 2016;30:101-8. [DOI: 10.1007/s10557-016-6654-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
11 Cho Y, Lee H, Park HK, Choe EY, Wang HJ, Kim RH, Kim Y, Kang ES. Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo. J Atheroscler Thromb 2020;27:429-40. [PMID: 31527323 DOI: 10.5551/jat.50039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151-167. [PMID: 23351925 DOI: 10.1016/j.cjca.2012.11.032] [Cited by in Crossref: 484] [Cited by in F6Publishing: 428] [Article Influence: 60.5] [Reference Citation Analysis]
13 Sunjaya AP, Sunjaya AF, Halim S, Ferdinal F. Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes. Int J Angiol 2018;27:121-31. [PMID: 30154630 DOI: 10.1055/s-0036-1572523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Lim S, Sakuma I, Quon MJ, Koh KK. Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal 2014;20:1286-99. [PMID: 23924053 DOI: 10.1089/ars.2013.5531] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
15 Kei AA, Filippatos TD, Elisaf MS. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opin Drug Saf 2016;15:559-69. [PMID: 26898906 DOI: 10.1517/14740338.2016.1157164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68. [PMID: 24267801 DOI: 10.1016/j.cjca.2013.09.023] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 13.8] [Reference Citation Analysis]
17 Goldstein MR, Mascitelli L. Do Statins Cause Diabetes? Curr Diab Rep 2013;13:381-90. [DOI: 10.1007/s11892-013-0368-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
18 Bardini G, Dicembrini I, Rotella CM, Giannini S. Lipids seasonal variability in type 2 diabetes. Metabolism 2012;61:1674-7. [DOI: 10.1016/j.metabol.2012.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
19 Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. J Cardiovasc Pharmacol Ther. 2013;18:113-118. [PMID: 23113965 DOI: 10.1177/1074248412463611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
20 Bahrami A, Bo S, Jamialahmadi T, Sahebkar A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev 2020;58:101024. [PMID: 32006687 DOI: 10.1016/j.arr.2020.101024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
21 Sattar N, Taskinen MR. Statins are diabetogenic--myth or reality? Atheroscler Suppl. 2012;13:1-10. [PMID: 22818818 DOI: 10.1016/j.atherosclerosissup.2012.06.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
22 Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol 2012;11:87. [PMID: 22831708 DOI: 10.1186/1475-2840-11-87] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
23 Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109-17. [PMID: 25754552 DOI: 10.1007/s00125-015-3528-5] [Cited by in Crossref: 171] [Cited by in F6Publishing: 155] [Article Influence: 28.5] [Reference Citation Analysis]
24 Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther 2013;18:13-8. [PMID: 22539817 DOI: 10.1177/1074248412444463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Sehra D, Sehra S, Sehra ST. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels? Expert Opin Drug Saf 2017;16:823-31. [PMID: 28571494 DOI: 10.1080/14740338.2017.1338269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev 2014;:CD010254. [PMID: 25415541 DOI: 10.1002/14651858.CD010254.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
27 Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013;231:8-14. [DOI: 10.1016/j.atherosclerosis.2013.08.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
28 Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. International Journal of Cardiology 2016;202:273-4. [DOI: 10.1016/j.ijcard.2015.08.130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
29 Laakso M, Kuusisto J. Diabetes Secondary to Treatment with Statins. Curr Diab Rep 2017;17:10. [PMID: 28155189 DOI: 10.1007/s11892-017-0837-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
30 Toth PP, Catapano AL, Farnier M, Foody J, Tomassini JE, Jensen E, Polis AB, Hanson ME, Musliner TA, Tershakovec AM. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. The American Journal of Cardiology 2016;118:1812-20. [DOI: 10.1016/j.amjcard.2016.08.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Barrios V, Escobar C, Cicero AFG, Burke D, Fasching P, Banach M, Bruckert E. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements 2017;24:1-15. [DOI: 10.1016/j.atherosclerosissup.2016.10.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
32 Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2018;60:229-39. [PMID: 29397561 DOI: 10.1007/s12020-018-1541-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
33 Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, Bajaj M. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014;28:447-457. [PMID: 25106875 DOI: 10.1007/s10557-014-6546-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
34 Kilic U, Gok O, Elibol-can B, Uysal O, Bacaksiz A. Efficacy of statins on sirtuin 1 and endothelial nitric oxide synthase expression: the role of sirtuin 1 gene variants in human coronary atherosclerosis. Clin Exp Pharmacol Physiol 2015;42:321-30. [DOI: 10.1111/1440-1681.12362] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
35 Farnier M, Colhoun HM, Sasiela WJ, Edelberg JM, Asset G, Robinson JG. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. Journal of Clinical Lipidology 2017;11:986-97. [DOI: 10.1016/j.jacl.2017.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
36 Ding C, Hu M, Wu YJ, Tomlinson B. Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia. Lipids Health Dis 2015;14:107. [PMID: 26365713 DOI: 10.1186/s12944-015-0116-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Sabir S, Akhtar MF, Saleem A. Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals. Environ Sci Pollut Res 2019;26:1277-86. [DOI: 10.1007/s11356-018-3774-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
38 Zhou Y, Yuan Y, Cai RR, Huang Y, Xia WQ, Yang Y, Wang P, Wei Q, Wang SH. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother 2013;14:1575-84. [PMID: 23826679 DOI: 10.1517/14656566.2013.810210] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
39 Turan A, Egan C, You J, Sessler D, Abdelmalak B. Effect of Statins on Insulin Requirements during Non-Cardiac Surgery. Anaesth Intensive Care 2014;42:350-5. [DOI: 10.1177/0310057x1404200312] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Bell DS, DiNicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab 2014;16:689-94. [PMID: 24373206 DOI: 10.1111/dom.12254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]